Primary prevention of sudden cardiac death: one step forwards and one step backwards
Michael E Cain
This article has no abstract so we have provided the first paragraph of the full text.
In 2006, ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a leading cause of mortality worldwide. Judging from data acquired in the US and Europe, VT/VF claims two to three lives per 100,000 individuals each year. The incidence of arrhythmic death has not declined in tandem with advances in the management of acute coronary syndromes, heart failure and cardiovascular disease in general. Primary prevention of sudden death is desirable. It requires accurate identification of patients at risk and effective therapies that prevent or terminate VT/VF.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
